All News
Iberdomide Efficacy in Cutaneous Lupus
Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
Read Article
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.
Read Article
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Dot the "i", Cross the "t" (10.11.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain
Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.
https://t.co/Ch5XYlq6lX
Dr. John Cush RheumNow ( View Tweet)
Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI
Dr. John Cush RheumNow ( View Tweet)
Filgotinib Efficacy and Safety - 3 Years Later
Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in… https://t.co/eABIG1Kal6 https://t.co/7ZphZALniE
Dr. John Cush RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush RheumNow ( View Tweet)
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
https://t.co/MYYBBIIuDA https://t.co/1AfbxCuGIq
Dr. John Cush RheumNow ( View Tweet)
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush RheumNow ( View Tweet)
US health expenditures grew from $4.1 trillion in 2020 to $4.5 trillion in 2022 (17.3% incr).
US saved >$400 billion in 2022 by using generic and biosimilar drugs, https://t.co/Z8kS4elyA3 https://t.co/3LopIiQiqZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush RheumNow ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush RheumNow ( View Tweet)
Health Disparities in DMARD Use in RA
A UK study shows biological and targeted synthetic DMARD (b/tsDMARDs) use in newly diagnosed rheumatoid arthritis (RA) varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
https://t.co/t7O99FM7fQ https://t.co/CtvfblpPUo
Dr. John Cush RheumNow ( View Tweet)
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/RGS2DJgzyS https://t.co/PhqXt0hIzY
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a 4th biosimilar to Stelara - the new agent, ustekinumab-srl (Imuldosa), is indicated for Rx of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Originator Stelara sales in 2023 were nearly $10.86 USD billion globally… https://t.co/MoNBj2UaVH https://t.co/3Tenkfq0KK
Dr. John Cush RheumNow ( View Tweet)
Risk of Uveitis with Spondyloarthritis
A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can… https://t.co/96rRu77Tyl https://t.co/bGHnZ7lCIm
Dr. John Cush RheumNow ( View Tweet)
